623564-30-7

Basic information

• Product Name: 5-TERT-BUTYL 2-ETHYL 6,7-DIHYDROTHIENO[3,2-C]PYRIDINE-2,5(4H)-DICARBOXYLATE
• Synonyms: 5-TERT-BUTYL 2-ETHYL 6,7-DIHYDROTHIENO[3,2-C]PYRIDINE-2,5(4H)-DICARBOXYLATE;6,7-DIHYDRO-4H-THIENO[3,2-C]PYRIDINE-2,5-DICARBOXYLIC ACID 5-TERT-BUTYL ESTER 2-ETHYL ESTER;6,7-DIHYDROTHIENO[3,2-C]PYRIDINE-2,5(4H)-DICARBOXYLIC ACID 5-(1,1-DIMETHYLETHYL) 2-ETHYL ESTER;Ethyl 5-Boc-4,5,6,7-tetrahydrothieno[3,2-c]pyridine-2-carboxylate;5-tert-butyl 2-ethyl 6,7-dihydrothieno[3,2-c]pyridine-2,5(4H)-di;6,7-Dihydro-4H-thiazolo[5,4-c]pyridine-2,5-dicarboxylic acid 5-tert-butyl ester 2-ethyl ester;5-tert-butyl 2-ethyl 4H,5H,6H,7H-thieno[3,2- c]pyridine-2,5-dicarboxylate;5-tert-butyl 2-ethyl 6,7-dihydro-1H-pyrrolo[3,2-c]pyridine-2,5(4H)-dicarboxylate
• CAS NO: 623564-30-7
• Molecular Formula: C₁₅H₂₁NO₄S
• Molecular Weight: 311.4
• Mol File: 623564-30-7.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 5-TERT-BUTYL 2-ETHYL 6,7-DIHYDROTHIENO[3,2-C]PYRIDINE-2,5(4H)-DICARBOXYLATE(CAS DataBase Reference)
• NIST Chemistry Reference: 5-TERT-BUTYL 2-ETHYL 6,7-DIHYDROTHIENO[3,2-C]PYRIDINE-2,5(4H)-DICARBOXYLATE(623564-30-7)
• EPA Substance Registry System: 5-TERT-BUTYL 2-ETHYL 6,7-DIHYDROTHIENO[3,2-C]PYRIDINE-2,5(4H)-DICARBOXYLATE(623564-30-7)

Safety Data

• Hazardous Substances Data: 623564-30-7(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
5-TERT-BUTYL 2-ETHYL 6,7-DIHYDROTHIENO[3,2-C]PYRIDINE-2,5(4H)-DICARBOXYLATE is used as a calcium channel blocker for its ability to relax and widen blood vessels, leading to improved blood flow and reduced blood pressure.
Used in Hypertension Treatment:
In the medical field, 5-TERT-BUTYL 2-ETHYL 6,7-DIHYDROTHIENO[3,2-C]PYRIDINE-2,5(4H)-DICARBOXYLATE is utilized as a therapeutic agent for treating hypertension, given its capacity to lower blood pressure by enhancing blood vessel dilation.
Used in Angina Treatment:
5-TERT-BUTYL 2-ETHYL 6,7-DIHYDROTHIENO[3,2-C]PYRIDINE-2,5(4H)-DICARBOXYLATE is employed as a potential treatment for angina, a condition characterized by chest pain due to insufficient blood flow to the heart. Its action as a calcium channel blocker can help alleviate the symptoms by improving blood flow to the heart muscle.
Used in Research and Development:
In the scientific community, 5-TERT-BUTYL 2-ETHYL 6,7-DIHYDROTHIENO[3,2-C]PYRIDINE-2,5(4H)-DICARBOXYLATE is used as a subject of study for its potential applications in various therapeutic areas, including cardiovascular diseases, due to its unique chemical properties and pharmacological actions.

Upstream product

• 885275-20-7 tert-butyl 4-chloro-5-formyl-3,6-dihydropyridine-1(2H)-carboxylate 
• 623-51-8 ethyl 2-sulfanylacetate 
• 24424-99-5 di-tert-butyl dicarbonate 
• 1190971-27-7 5-benzyl 2-ethyl 6,7-dihydrothieno[3,2-c]pyridine-2,5(4H)-dicarboxylate 
• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 
• 230301-73-2 6,7-dihydro-4H-thieno[3,2-c]-pyridine-5-carboxylic acid tert-butyl ester 
• 541-41-3 chloroformic acid ethyl ester 
• 1190971-25-5 benzyl 4-chloro-3-formyl-5,6-dihydropyridine-1(2H)-carboxylate 

Downstream Products

• 165947-48-8 5-tert-butoxycarbonyl-4,5,6,7-tetrahydrothieno[3,2-c]pyridine-2-carboxylic acid 
• 1190970-06-9 2-((1-(4-methoxy-2,6-dimethylphenylsulfonyl)piperidin-2-yl)methoxy)-1-(2-(piperidin-1-ylmethyl)-6,7-dihydrothieno[3,2-c]pyridin-5(4H)-yl)ethanone 
• 1190970-43-4 2-[[(2S)-1-[(4-methoxy-2,6-dimethyl-phenyl)sulfonyl]-piperidin-2-yl]-methoxy]-1-[2-(pyrrolidin-1-yl-methyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl]-ethanone 
• 1190970-05-8 (R)-N-(3-oxo-1-phenyl-3-(2-(piperidin-1-ylmethyl)-6,7-dihydrothieno[3,2-c]pyridin-5(4H)-yl)propyl)naphthalene-2-sulfonamide 
• 1190970-07-0 4-methoxy-N,2,6-trimethyl-N-(2-(2-oxo-2-(2-(piperidin-1-ylmethyl)-6,7-dihydrothieno[3,2-c]pyridin-5(4H)-yl)ethoxy)ethyl)benzenesulfonamide 
• 1190970-37-6 N-[2-[2-[2-(azetidin-1-yl-methyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl]-2-oxo-ethoxy]-ethyl]-2-chloro-N-cyclopropyl-6-methyl-benzenesulfonic acid amide 

Relevant articles and documents

Discovery of 2-substituted-N-(3-(3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)-1,2,3,4-tetrahydroisoquinoline-6-carboxamide as potent and selective protein arginine methyltransferases 5 inhibitors: Design, synthesis and biological evaluation

Protein arginine methyltransferases 5 (PRMT5) represents an attractive drug target in epigenetic field for the treatment of leukemia and lymphoma. Here, a series of N-(3-(3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)amide derivatives targeting PRMT5 were designed with structure-based approach and synthesized. Among them, compound 46 showed potent and selective PRMT5 inhibition activity with an IC50 of 8.5 nM, which was approximately equivalent with the phase I clinical trial PRMT5 inhibitor GSK-3326595 (IC50 = 5.5 nM). Compound 46 also displayed pronounced anti-proliferative activity in MV4-11 cells (GI50 = 18 nM) and antitumor activity in MV4-11 mouse xenografts model. This molecule can serve as an excellent tool compound for probing the biological function of PRMT5.

Synthesis, characterization and anticancer activity of 5-substituted 4,5,6,7-tetrahydro-N-(tetrahydro-2H-pyran-4-yl)thieno[3,2-c]pyridine-2-carboxamide derivatives

4,5,6,7-Tetrahydrothieno pyridine (THTP) and their derivatives are an important heterocyclic compounds that exhibits various biological activities viz.,antimicrobial activity, antileishmanial activity, antiarrhythmic activity, antiinflammatory activity, antihyperlipidemic activity, antidepressant activity, anticancer activity, antiplatelet activity and antidiabetic etc. The present study describes the synthesis, characterization and in vitro cytotoxic potential against human lung carcinoma of some novel derivatives of 4,5,6,7-tetrahydrothieno[3,2-c]pyridine (7A-M) with benzylic and amide substitution on the nitrogen atom of tetrahydro theino pyridine ring. The synthetic steps involves (i) Vilsmeyer protocol in step 1 (ii) formation of tetrahydothieno[3,2-c]pyridine ring in presence of 2-mercaptoacetate in step 2 (iii) alkaline hydrolysis followed by amide coupling with tetrahydro-2H-pyran-4-amine in step 3 and step 4. The newly synthesized compounds 7A-M was sufficiently characterized by 1 H NMR, IR and mass techniques. Furthermore, these derivatives were screened for their in vitro cytotoxic potential against human lung carcinoma (HCT-116) cell line using the MTT assay. Compound 7B (IC50: 69.52 μg) and compound 7K (IC50: 66.35 μg) exhibited significant activity at micro molar concentration when compared to standard drug camptothecin.

CYCLOPROPYL-AMIDE COMPOUNDS AS DUAL LSD1/HDAC INHIBITORS

The present disclosure describes novel compounds of the general Formula (I), their analogs, tautomeric forms, stereoisomers, polymorphs, hydrates, solvates, pharmaceutically acceptable salts, pharmaceutical compositions, metabolites, and prodrugs thereof. These compounds can inhibit both LSD and HDAC and are useful as therpeautic or ameliorating agent for diseases that are involved in cellular growth such as malignant tumors, schizophrenia, Alzheimer's disease, parkinson's disease and the like.

Design, synthesis and evaluation of novel tetrahydrothieno[3,2-c]pyridine derivatives as potent smoothened antagonists

Hedgehog (Hh) signalling plays an important role in embryonic development and adult tissue homeostasis. Since activation of the Hh signalling pathway is implicated in several types of human cancers, inhibitors of this pathway could be promising anticancer

BIARYL COMPOUNDS USEFUL FOR THE TREATMENT OF HUMAN DISEASES IN ONCOLOGY, NEUROLOGY AND IMMUNOLOGY

The present invention provides compounds and compositions thereof which are useful as inhibitors of Bruton's tyrosine kinase and which exhibit desirable characteristics for the same.

Potent histone deacetylase inhibitors derived from 4-(aminomethyl)-N- hydroxybenzamide with high selectivity for the HDAC6 isoform

A screen for HDAC6 inhibitors identified acyl derivatives of 4-(aminomethyl)-N-hydroxybenzamide as potent leads with unexpected selectivity over the other subtypes. We designed and synthesized constrained heterocyclic analogues such as tetrahydroisoquinolines that show further enhanced HDAC6 selectivity and inhibitory activity in cellular assays. Selectivity may be attributed to the benzylic spacer more effectively accessing the wider channel of HDAC6 compared to other HDAC subtypes as well as hydrophobic capping groups interacting with the protein surface near the rim of the active site.

HISTONE DEACETYLASE INHIBITORS

Provided herein are isoform selective histone deacetylase inhibitors of the formula (I), their derivatives, analogs, tautomeric forms, stereoisomers, polymorphs, hydrates, metabolites, prodrugs, solvates, pharmaceutically acceptable salts and compositions thereof. These compounds are isoform selective inhibitors of HDACs and are useful as a therapeutic or ameliorating agent for diseases that are involved in cellular growth such as cancer, malignant tumors, autoimmune diseases, skin diseases, fungal infections, protozoal infections, HIV, inflammation and CNS disorders.

SUBSTITUTED PYRROLIDINE AMIDES, THE PRODUCTION THEREOF, AND THE USE THEREOF AS MEDICATIONS

The object of the present invention is novel substituted pyrrolidine amides of the general formula (I) in which D, L. E, G, J, M, L1, L2, R4, and R5 are defined as in the specification, the tautomers, enantiomers, diastereomers, mixtures, and salts thereof, particularly physiologically tolerated salts with inorganic or organic acids or bases having valuable properties.

NOVEL CC-1065 ANALOGS AND THEIR CONJUGATES

This invention relates to novel analogs of the DNA-alkylating agent CC-1065 and to their conjugates. Furthermore this invention concerns intermediates for the preparation of said agents and conjugates. The conjugates are designed to release their (multiple) payload after one or more activation steps and/or at a rate and time span controlled by the conjugate in order to selectively deliver and/or controllably release one or more of said DNA alkylating agents. The agents, conjugates, and intermediates can be used to treat an illness that is characterized by undesired (cell) proliferation. As an example, the agents and the conjugates of this invention may be used to treat a tumor.

SUBSTITUTED SULFONAMIDE DERIVATIVES

The invention relates to substituted sulfonamide derivatives, processes for the preparation thereof, medicaments containing these compounds and the use of substituted sulfonamide derivatives for the preparation of medicaments.